Details
Stereochemistry | ACHIRAL |
Molecular Formula | C4H11Cl2N2O2P.C4H11NO3 |
Molecular Weight | 342.157 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(CO)(CO)CO.OP(=O)(NCCCl)NCCCl
InChI
InChIKey=PGLRCMRTUIMSFQ-UHFFFAOYSA-N
InChI=1S/C4H11Cl2N2O2P.C4H11NO3/c5-1-3-7-11(9,10)8-4-2-6;5-4(1-6,2-7)3-8/h1-4H2,(H3,7,8,9,10);6-8H,1-3,5H2
Molecular Formula | C4H11NO3 |
Molecular Weight | 121.135 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C4H11Cl2N2O2P |
Molecular Weight | 221.022 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Palifosfamide or ZIO-201 (isophosphoramide mustard; IPM), a bi-functional DNA alkylator, is the active metabolite of ifosfamide (IFOS). IFOS and the related drug cyclophosphamide (CPA) are widely used anti-cancer drugs. Both are pro-drugs and need to be metabolized to be active. Their clinical use is limited by the toxicity associated with some of their metabolites. Palifosfamide has shown efficacy in diverse cancer models. ZIOPHARM Oncology Inc, under license from Dekk-Tec Inc, was developing palifosfamide, a formulation of isophosphoramide mustard with tris(hydroxymethyl)aminomethane salt-stabilization (palifosfamide-tris) and previously with lysine-stabilization (palifosfamide-lys). Preclinical studies and phase I and I/II clinical trials demonstrated that palifosfamide-tris had an antitumor efficiency comparable or superior to that of ifosfamide. To date ZIO-201 is not present in ZIOPHARM pipeline.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Phosphate prodrugs of isophosphoramide mustard. | 2003 Mar-Apr |
|
Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma. | 2009 Sep |
|
Palifosfamide, a bifunctional alkylator for the treatment of sarcomas. | 2010 Jan |
|
Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. | 2012 Feb |
|
PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. | 2016 Nov 10 |
|
Carboplatin and Etoposide With or Without Palifosfamide in Untreated Extensive-Stage Small-Cell Lung Cancer: A Multicenter, Adaptive, Randomized Phase III Study (MATISSE). | 2017 Aug 10 |
|
The fate of new fosfamides in phase III studies in advanced soft tissue sarcoma. | 2017 Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27621408
PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma.
Patients were randomly assigned 1:1 to receive doxorubicin 75 mg/m2 intravenously day 1 plus palifosfamide 150 mg/m2/d intravenously days 1 to 3 or doxorubicin plus placebo once every 21 days for up to six cycles. The primary end point was progression-free survival (PFS) by independent radiologic review.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19224214
Palifosfamide lysine was cytotoxic against all the osteosarcome cell lines tested with the IC(50) ranging from 0.5 to 1.5 microg/ml except for OS222, which had an IC(50) of 7 microg/ml.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:41:08 GMT 2023
by
admin
on
Sat Dec 16 01:41:08 GMT 2023
|
Record UNII |
0X5A3C04ID
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C697
Created by
admin on Sat Dec 16 01:41:08 GMT 2023 , Edited by admin on Sat Dec 16 01:41:08 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C95703
Created by
admin on Sat Dec 16 01:41:08 GMT 2023 , Edited by admin on Sat Dec 16 01:41:08 GMT 2023
|
PRIMARY | |||
|
100000137631
Created by
admin on Sat Dec 16 01:41:08 GMT 2023 , Edited by admin on Sat Dec 16 01:41:08 GMT 2023
|
PRIMARY | |||
|
0X5A3C04ID
Created by
admin on Sat Dec 16 01:41:08 GMT 2023 , Edited by admin on Sat Dec 16 01:41:08 GMT 2023
|
PRIMARY | |||
|
DTXSID00147888
Created by
admin on Sat Dec 16 01:41:08 GMT 2023 , Edited by admin on Sat Dec 16 01:41:08 GMT 2023
|
PRIMARY | |||
|
46926367
Created by
admin on Sat Dec 16 01:41:08 GMT 2023 , Edited by admin on Sat Dec 16 01:41:08 GMT 2023
|
PRIMARY | |||
|
SUB76137
Created by
admin on Sat Dec 16 01:41:08 GMT 2023 , Edited by admin on Sat Dec 16 01:41:08 GMT 2023
|
PRIMARY | |||
|
AB-06
Created by
admin on Sat Dec 16 01:41:08 GMT 2023 , Edited by admin on Sat Dec 16 01:41:08 GMT 2023
|
PRIMARY | |||
|
CHEMBL889
Created by
admin on Sat Dec 16 01:41:08 GMT 2023 , Edited by admin on Sat Dec 16 01:41:08 GMT 2023
|
PRIMARY | |||
|
1070409-31-2
Created by
admin on Sat Dec 16 01:41:08 GMT 2023 , Edited by admin on Sat Dec 16 01:41:08 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |